Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study
Authors' conclusion
PGDP levels in response to liraglutide and naltrexone/bupropion are associated with improvements in metabolism. Our study provides support for the administration of the downregulated members of the PGDP family as replacement therapy (e.g. glucagon), in addition to the medications currently in use that induced their downregulation (e.g. GLP-1), and future studies should explore whether the addition of other PGDPs (e.g. GLP-2) could offer additional benefits.
Study context
- Population
- Patients with obesity or with overweight and co-morbidities, without diabetes
- Participants
- 17 patients
- Comparison
- Naltrexone/bupropion vs liraglutide
- Naltrexone/bupropionn = 8
- Liraglutiden = 9
- Outcome
- Changes in circulating levels of all proglucagon-derived peptides (PGDPs)
- Follow-up
- 3 and 6 months
Methodological details6-month
- 6-month
Main finding
As reported in the abstract
Circulating PGDP levels
- Naltrexone/bupropion: weight-independent increase in proglucagon
- P < .001
- Naltrexone/bupropion: decreases in GLP-2, glucagon and major proglucagon fragment
- P ≤ .01
- Liraglutide: weight-independent upregulation of total GLP-1
- P = .04
- Liraglutide: downregulation of major proglucagon fragment, GLP-2 and glucagon
- P < .01
Further findings
Body weight, composition, metabolism and liver
- Both medications improved body weight and composition, carbohydrate and lipid metabolism, and liver fat and function
Association of 3-month PGDP levels with metabolic changes · 3 and 6 months
- PGDP levels at 3 months positively and independently correlated with improvements in fat mass, glycaemia, lipaemia and liver function, and negatively with reductions in fat-free mass
Original publication
Circulating levels of proglucagon‐derived peptides are differentially regulated by the glucagon‐like peptide‐1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6‐month long interventional study. Diabetes Obes Metab. Published 29 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →